Delivering optimal care for inflammatory bowel disease patients in Scotland in 2014

被引：0
作者：
Gaya, Daniel R. [1 ]
机构：
[1] Glasgow Royal Infirm, Gastroenterol Unit, Glasgow G4 0SF, Lanark, Scotland
来源：
SCOTTISH MEDICAL JOURNAL | 2014年 / 59卷 / 02期
关键词：
Crohn's disease; inflammatory bowel disease; ulcerative colitis; CROHNS-DISEASE; FECAL CALPROTECTIN; THIOPURINE METHYLTRANSFERASE; AZATHIOPRINE THERAPY; COST-EFFECTIVENESS; SMOKING-CESSATION; OUTCOMES; METHOTREXATE; ALLOPURINOL; MANAGEMENT;
D O I：
10.1177/0036933014531540
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The inflammatory bowel diseases (IBDs), Crohn's disease and ulcerative colitis, present an ever increasing burden to the healthcare systems in the Western world. Scotland in particular has seen a significant increase in both diseases, particularly Crohn's disease. It is thus of paramount importance that secondary care services within Scotland are equipped to cope with this increased demand at a time when the treatment options are broadening, patients expectations are increasing and healthcare budgets face major restriction. This article outlines some aspects of optimal delivery of an IBD service in secondary care.
引用
收藏
页码：130 / 135
页数：6
相关论文
共 43 条
  • [1] Alfadhli AA, 2005, COCHRANE DB SYST REV, V1
  • [2] [Anonymous], NICE TECHN APPR GUID
  • [3] Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease
    Ansari, A.
    Arenas, M.
    Greenfield, S. M.
    Morris, D.
    Lindsay, J.
    Gilshenan, K.
    Smith, M.
    Lewis, C.
    Marinaki, A.
    Duley, J.
    Sanderson, J.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (08) : 973 - 983
  • [4] The place of varenicline in smoking cessation treatment
    Aveyard, Paul
    [J]. THORAX, 2008, 63 (08) : 666 - 668
  • [5] Tolerability of Shortened Infliximab Infusion Times in Patients With Inflammatory Bowel Diseases: A Single-Center Cohort Study
    Breynaert, Christine
    Ferrante, Marc
    Fidder, Herma
    Van Steen, Kristel
    Noman, Maja
    Ballet, Vera
    Vermeire, Severine
    Rutgeerts, Paul
    Van Assche, Gert
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (04) : 778 - 785
  • [6] Fecal calprotectin: Validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease
    Bunn, SK
    Bisset, WM
    Main, MJC
    Gray, ES
    Olson, S
    Golden, BE
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2001, 33 (01) : 14 - 22
  • [7] Parenteral methotrexate for patients with Crohn's disease: how to develop a high-quality and safe self-administration service
    Coltart, Iona
    Blackmore, Laura
    Caisley, Jane
    Harris, Adam
    [J]. FRONTLINE GASTROENTEROLOGY, 2012, 3 (01) : 36 - 38
  • [8] Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease
    Costa, F
    Mumolo, MG
    Ceccarelli, L
    Bellini, M
    Romano, MR
    Sterpi, C
    Ricchiuti, A
    Marchi, S
    Bottai, M
    [J]. GUT, 2005, 54 (03) : 364 - 368
  • [9] Role of faecal calprotectin as non-invasive marker of intestinal inflammation
    Costa, F
    Mumolo, MG
    Bellini, M
    Romano, MR
    Ceccarelli, L
    Arpe, P
    Sterpi, C
    Marchi, S
    Maltinti, G
    [J]. DIGESTIVE AND LIVER DISEASE, 2003, 35 (09) : 642 - 647
  • [10] Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease
    Cuffari, C
    Hunt, S
    Bayless, T
    [J]. GUT, 2001, 48 (05) : 642 - 646
12345